LeonaBio to Present ATH-1105 Trial Design June 3 in Boston; Oncology Panel June 24 in San Diego
LONA•LeonaBio will present its lead candidate ATH-1105 at the 5th Annual ALS Drug Development Summit in Boston on June 3, detailing strategic trial design and biomarker integration. The company will also discuss oncology trial alignment and investment in a June 24 panel at the BIO International Convention in San Diego.
1. ALS Summit Presentation
LeonaBio will deliver an oral presentation titled "Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive Methodologies" at the 5th Annual ALS Drug Development Summit in Boston on June 3 at 2:50 p.m. ET, highlighting trial design strategies for its lead candidate ATH-1105 in ALS.
2. BIO International Convention Panel
At the BIO International Convention in San Diego on June 24 at 11:00 a.m. PT, LeonaBio’s oncology consultant David Portman will join a panel on "The Future of Oncology Trials: Aligning Science, Regulation, and Investment in Overall Survival", discussing regulatory alignment and investment strategies focused on overall survival endpoints.
3. LeonaBio Pipeline and Strategy
LeonaBio is a clinical-stage biopharmaceutical company developing small molecule therapies lasofoxifene and ATH-1105 for treatment-resistant metastatic breast cancer and ALS, focusing on novel trial designs and biomarker-driven approaches to address high unmet medical needs.
